

VPA10539/008/001

**Vey Tosal 100 mg/ml + 0.05 mg/ml solution for injection for horses, cattle, dogs and cats**

Variation	Summary	Date
Vet - C6	VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17	17/02/25
Vet - C1	VNRA - Vet - C1 - Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV) - C1 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV)	17/02/25
Vet - G.I.2 b)	VRA-S - Vet - G.I.2 b) - b) Harmonisation of the generic/hybrid product according to article 71(1) after SPC harmonisation of the reference product - G.I.2 b) Safety, Efficacy, Pharmacovigilance changes - Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid medicinal product following assessment of the same change for the reference product - Harmonisation of the generic/hybrid product according to article 71(1) after SPC harmonisation of the reference product	07/02/25
Vet - G.I.18	VRA-S - Vet - G.I.18 - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004 - G.I.18 Safety, Efficacy, Pharmacovigilance changes - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	07/02/25
Vet - F.I.a.1 a)	VRA-S - Vet - F.I.a.1 a) - a) Introduction of a manufacturer of the active substance supported by an ASMF - F.I.a.1 a) - Quality Changes - Active Substance - Manufacture - Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier -	27/05/24

	Introduction of a manufacturer of the active substance supported by an ASMF	
Vet - C1	VNRA - Vet - C1 - Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV) - C1 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV)	22/11/23
Vet - C6	VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17	22/11/23
Vet - F.II.f.1 z)	VRA-R - Vet - F.II.f.1 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.f.1 z) Quality Changes -Stability - Change in the shelf-life or storage conditions of the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	03/11/23